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Abstract: The influence of area-based and individual indicators of socioeconomic status (SES) on
health-related quality of life (HRQOL) and patient concerns following head and neck cancer is
complex and under-reported. The aim of this study is to use baseline data collected as part of
a randomised controlled trial to provide greater detail on the attribution of SES to University of
Washington Quality of Life version 4 (UWQOL v4), Distress Thermometer and European Quality of
Life Five-Dimension Five-Level (EQ-5D-5L) outcomes. A total of 288 trial patients attended baseline
clinics a median (Interquartile (IQR)) of 103 (71–162) days after the end of treatment. Area-based SES
was assessed using the Index of Multiple Deprivation (IMD) 2019. Thirty-eight per cent (110/288)
of patients lived in the most deprived IMD rank quintile. Less than good overall quality of life
(31% overall) was associated with current working situation (p = 0.008), receipt of financial benefits
(p < 0.001), total household income (p = 0.003) and use of tobacco (p = 0.001). Income and employment
were significant patient level indicators predictors of HRQOL outcomes after case-mix adjustment.
The number of Patient Concerns Inventory items selected varied significantly by overall clinical
tumour clinical stage (p < 0.001) and by treatment (p < 0.001) but not by area IMD or patient-level
deprivation indicators. In conclusion, interventions to improve employment and finance could make
a substantial positive effect on HRQOL outcomes and concerns.
Keywords: social determinants; financial toxicity; health-related quality of life; head and neck cancer;
quality of life; survivorship
1. Introduction
The term ‘determinants of health’ was introduced in the 1970s and refers to factors that
have a significant influence, positive or negative, on health [1]. These may be biological,
behavioural, sociocultural, economic and ecological [2]. The determinants of health can be
divided into four categories: nutrition, lifestyle, environment and genetics [3]. Evidence
shows that the incidence of cancer and chronic diseases share modifiable risk factors such
as alcohol consumption, cigarette smoking, unhealthy diet and physical inactivity [4]. Some
determinants are modifiable such as nutrition and lifestyle. People should be encouraged
and supported in making modifications where possible, and this is an integral component
of cancer care [4].
Head and neck cancer (HNC) is associated with social inequalities as reflected by
its higher incidence in lower socio-economic groups (SESG) [5]. Of the determinants of
health nutrition and lifestyle areas that can be usefully addressed in those with HNC,
smoking and alcohol are the main risk lifestyle factors and are more prevalent in lower
SESG [6]. After diagnosis and treatment, a high proportion of head and neck cancer
survivors reduce their work capacity, and many do not return to work following cancer
treatment. This can have further implications for their finances [7]. Socioeconomic position
and deprivation have consequences in the utilisation of healthcare [8,9] and this is related
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to diagnosis and treatment and results in unmet needs. Regarding unmet needs, HNC
patients tend not to actively pursue support compared to their less disadvantaged peers [10].
Socioeconomic and other demographic disparities predict survival even when there is
equal access to care [11] and are associated with unmet needs and poor health-related
quality of life (HRQOL).
Many factors are associated with poorer HRQOL outcomes following HNC, such as
site, stage and treatment [12]. HNC cancer patients often live in poor socioeconomic areas
and those most deprived do tend to report poor HRQOL [13]. Differences in HRQOL are
reflected in differences in Index of Multiple Deprivation (IMD) scores [14].
The authors have been involved in a randomised trial involving the use of a patient
prompt list (Patient Concerns Inventory) in routine review consultant consultations, a trial
which indicated benefits in quality of life and socio-emotional dysfunction compared to
standard care [15]. Trial casemix information included both area- and individual-based
socio-economic characteristics [16]. With this detail, secondary analyses were possible;
hence the aim of this study was to focus on SES and add greater definition and understand-
ing to the contribution of the area and patient indicators of SES as factors affecting HRQOL
outcomes after HNC. This information will allow for a better appreciation amongst the
head and neck multi-professional team and for closer collaboration across primary and
secondary care to potentially improve outcomes for more disadvantaged HNC patients.
2. Methods
The data came from a pragmatic cluster-controlled trial at two UK Cancer Centres,
Aintree and Leeds. Consultants (clusters) were randomised to ‘using’ or ‘not using’ an
intervention incorporating the Patient Concerns Inventory (PCI) prompt list at all their
trial clinics. The full methodology has been described previously [17]. Eligible patients
were treated curatively for primary HNC, with all sites, stages of disease and treatments
included. Palliation and recurrence were exclusion criteria, as were cognitive impairment,
psychoses or dementia. The PCI consists of 56 clinical items [18], which patients select from
before their appointment, to help guide the outpatient consultation through the symptoms
and problems experienced following treatment for HNC. Patients were first discussed
at multi-disciplinary team (MDT) meetings (tumour board) between January 2017 and
December 2018, with baseline clinics between April 2017 and October 2019. HRQOL
data from the first post-treatment (trial baseline) consultation with consultant surgeon
were analysed.
Ranks from the Index of Multiple Deprivation (IMD 2019) were derived from patient
postcodes using publicly available data [19] for 32,844 small areas within England. Overall
ranks were analysed as quintile categories ranging from the 20% of most deprived areas
in England to the 20% least deprived. A baseline clinic questionnaire collected individual
SES deprivation-related information as to whether patients lived alone or with others,
were working, had ever been unemployed, were receiving financial benefits and their total
household income before tax. Lifestyle factors regarding the use of tobacco and alcohol
were also collected, as were patient ethnicity, gender and age. Clinical details about primary
tumour site, grade, treatment and comorbidity were obtained from clinical records.
The UW-QOLv4 questionnaire contains 12 single-question domains, with 3–5 evenly
scaled response options from 0 (worst) to 100 (best) [20]. Regarding overall QOL, patients
were asked to consider not just physical and mental health, but also many other factors,
such as family, friends, spirituality or personal leisure activities that were important
to their enjoyment of life. Subsequent work developed subscale composite scores [21]
and domain algorithms screening for significant problems/dysfunction [22]. Question
domains for intimacy and fears of recurrence were also developed using a similar system
of hierarchical responses, as for the UWQOL v4 [23,24]. HRQOL data also included the
Distress Thermometer (DT) and EQ-5D-5L [25,26]. The pre-specified primary outcome
measure of the trial was the percentage with less than good overall QOL (UWQOLv4)
at 12 months after the baseline clinic. Two pre-specified secondary outcomes were the
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percentage with a DT score ≥4 and the mean social–emotional subscale score of the
UWQOLv4. This paper analyses these and other HRQOL measures at the baseline clinic.
3. Statistical Analyses
Mann–Whitney (2 groups) or Kruskal–Wallis (>2 groups) tests were used to compare
patient groups by UWQOL social–emotional and physical subscale scores, EQ5D-5L VAS
and time trade-off (TTO) values, and by the total number of PCI items selected. Fishers
exact test was used to assess the association between patient characteristics and of those
with binary HRQOL outcomes. Logistic regression was used to assess whether any of
the deprivation indicators (IMD 2019, living alone, currently working, receiving financial
benefits, ever been unemployed, total household income, use of tobacco and alcohol) were
predictive of HRQOL outcomes after adjustment for trial location, age, gender, tumour
site, stage and treatment, and Adult Comorbidity Evaluation (ACE-27) comorbidity. The
adjustment variables were all forced into the model as independent predictors, and then the
deprivation indicators were considered as additional independent predictors with p < 0.01
criteria for stepwise entry. Analysis with SPSS (IBM Corp. Released 2017. IBM SPSS
Statistics for Windows, Version 25.0. Armonk, NY, USA) gave the NagelKerke R2 statistic
(range 0–1) as an estimate of how much variation in binary outcomes was explained by
‘predictor’ factors in the logistic regression model. In recognition of the numerous tests,
p < 0.01 was taken as a better reflection of statistical significance.
The study was conducted according to the guidelines of the Declaration of Helsinki
and approved given on 8 July 2016 by the North West-Liverpool Central Research Ethics
Committee REC reference: IRAS 16/NW/0465, Project ID: 189554. It also has approval from
the Health Research Authority (HRA) and the Research and Development Department at
Aintree University Hospital National Health Service.
4. Results
The 288 trial patients attended baseline clinics a median (IQR) of 194 (125–249) days
after diagnosis and 103 (71–162) days after the end of treatment. Median (IQR) age at
baseline clinic was 62 (55–69) years and 69% (198) were male. Patient characteristics are
shown in Table 1. Thirty-eight per cent (110/288) of patients lived in the most deprived
20% of small-area neighbourhoods in England as measured by IMD rank quintiles. The
trial groups (140 PCI, 148 no PCI) were well matched at baseline in regard to the primary,
secondary and other HRQOL measures analysed in this paper [16].



















Overall stage Early 0–2 124 43
Advanced 3–4 164 57




Surgery only, no FF 95 33
Surgery only, and FF 21 7
RT/CT only 58 20
Surgery & RT/CT, no FF 68 24





Ethnic group Caucasian 279 97
Other 9 3
IMD 2019 quintile




5 best 34 12
Currently living in house
or flat
With other 220 76
Alone 65 23












Not known 23 8
Total household income-all
sources before tax
<GBP 12,000 52 18
GBP 12,000–22,999 47 16
GBP 23,000–34,999 46 16
≥GBP 35,000 56 19










Not known 8 3
Less than good overall quality of life (31% overall) was associated (Table 2) with
current working situation (p = 0.008), receipt of financial benefits (p < 0.001), total household
income (p = 0.003) and use of tobacco (p = 0.001). For working patients, this was 20%
compared with 36% if not working. It was 43% for those on benefits and 22% without
benefits, 50% for patients in households with <£12,000 annual income and 20–23% for
higher-income groups. It was 57% for current users of tobacco. A distress thermometer
score of ≥4 (45% overall) was associated (also Table 2) with ever having been unemployed
(p = 0.002), receipt of financial benefits (p < 0.001) and use of alcohol (p = 0.007). It was
55% for patients having been unemployed compared with 36% otherwise. It was 58% if
receiving benefits and 34% without benefits and 60% for former users of alcohol. The trends
observed across the other four HRQOL measures in Table 2 suggest worse HRQOL reported
by patients who were younger, had tumours located in the oral cavity or oropharynx, had
tumours at an advanced stage, had ACE-27 comorbidity, were living in more deprived IMD
neighbourhoods, were currently not working, had known unemployment, were receiving
benefits, were living in lower income households and were current users of tobacco and
former users of alcohol.
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Subscale Score EQ-5D-5L VAS EQ-5D-5L TTO
Patients % n p-Value % n p-Value Median IQR p-Value Median IQR p-Value Median IQR p-Value Median IQR p-Value
Total 288 31 89 45 129 75 59–88 69 54–86 75 60–86 0.77 0.64–0.88
Location Aintree 178 26 47 0.05 45 80 >0.99 75 61–88 0.78 69 56–84 0.74 76 60–85 0.89 0.76 0.65–0.88 0.33
Leeds 110 38 42 45 49 75 58–88 68 53–86 75 50–88 0.78 0.64–0.88
Age <55 71 37 26 0.13 52 37 0.02 68 55–87 0.002 66 54–87 0.41 75 60–89 0.59 0.74 0.59–0.84 0.04
55–64 116 33 38 47 55 77 56–87 68 53–81 75 50–86 0.77 0.59–0.84
65–74 67 30 20 45 30 76 65–91 69 59–88 75 61–88 0.80 0.66–1.00
≥75 34 15 5 21 7 87 71–96 75 56–93 80 70–85 0.84 0.72–0.91
Gender Male 198 30 60 0.78 44 88 0.90 78 61–91 0.15 69 55–86 0.43 75 60–86 0.74 0.77 0.65–0.88 0.62
Female 90 32 29 46 41 71 57–87 68 54–82 77 51–85 0.76 0.63–0.88
Tumour site
Oral cavity 134 37 49 0.27 47 63 0.11 71 55–87 0.002 66 50–82 <0.001 71 50–84 0.05 0.75 0.58–0.88 0.01
Oropharynx 91 25 23 51 46 72 63–87 66 54–74 75 69–85 0.74 0.65–0.84
Larynx 41 29 12 34 14 87 75–95 90 73–95 80 64–90 0.84 0.72–1.00
Other 22 23 5 27 6 81 66–91 77 59–92 86 73–90 0.82 0.67–0.91
Overall Early 0–2 124 28 35 0.44 38 47 0.04 83 63–91 0.001 79 65–95 <0.001 79 53–88 0.49 0.77 0.64–0.88 0.22
stage Advanced 3–4 164 33 54 50 82 71 58–87 63 50–73 75 60–86 0.76 0.64–0.84
Treatment
Surgery only, no FF 95 19 18 0.01 33 31 0.03 84 68–92 <0.001 86 71–95 <0.001 80 67–90 0.07 0.84 0.70–0.91 0.09
Surgery only, & FF 21 33 7 67 14 67 48–87 61 35–75 79 56–86 0.71 0.62–0.84
RT/CT only 58 38 22 50 29 75 59–88 65 50–79 75 60–85 0.75 0.61–0.88
Surgery & RT/CT,
no FF 68 31 21 47 32 71 61–83 66 57–74 75 61–84 0.75 0.65–0.84
Surgery & RT/CT,
and FF 46 46 21 50 23 66 52–83 53 39–68 70 50–85 0.74 0.53–0.91
ACE27
comorbidity
None 137 24 33 0.02 40 55 0.32 78 63–91 0.21 71 61–89 0.007 80 69–90 0.003 0.80 0.70–0.88 0.02
Mild 95 33 31 49 47 73 58–87 68 54–83 70 50–83 0.74 0.58–0.88
Mod/severe 56 45 25 48 27 75 54–88 61 39–81 71 51–81 0.69 0.53–0.88
Ethnic
group
White British 279 30 84 0.14 44 122 0.08 75 61–88 0.21 69 55–86 0.43 78 60–86 0.10 0.77 0.64–0.88 0.36
Other 9 56 5 78 7 69 na 62 na 70 na 0.72 na
IMD 2019
quintile
1 worst 110 37 41 0.19 50 55 0.29 70 54–87 0.05 65 50–83 0.09 70 50–82 0.004 0.74 0.54–0.88 0.19
2 40 35 14 53 21 71 61–86 68 50–88 72 52–84 0.75 0.58–0.85
3 49 29 14 41 20 78 65–91 72 61–84 79 71–89 0.77 0.70–0.88
4 55 25 14 35 19 78 65–92 69 57–87 81 65–90 0.81 0.68–0.88




With other 220 31 69 0.88 48 105 0.06 74 59–87 0.09 68 54–84 0.60 75 60–86 0.41 0.77 0.64–0.85 0.38
Alone 65 29 19 34 22 83 61–91 71 53–88 75 54–84 0.77 0.63–0.91
Not known 3 1 2 55 na 67 na 90 na 0.72 na
Currently
working
Yes 88 20 18 0.008 40 35 0.25 82 70–91 <0.001 75 62–91 <0.001 80 70–90 <0.001 0.80 0.74–0.98 <0.001
No 192 36 70 47 91 71 55–87 66 50–79 71 50–82 0.74 0.55–0.84
Not known 8 1 3 77 na 85 na 84 na 0.84 na









Subscale Score EQ-5D-5L VAS EQ-5D-5L TTO




Yes 110 35 38 0.23 55 61 0.002 71 54–87 0.001 66 50–79 0.002 70 50–81 <0.001 0.72 0.56–0.84 0.001
No 162 27 44 36 58 78 66–91 71 59–90 80 70–90 0.80 0.69–0.88
Not known 16 7 10 68 53–82 69 49–95 71 50–85 0.74 0.52–0.87
Financial
Benefits
None 158 22 34 <0.001 34 54 <0.001 81 68–91 <0.001 73 61–90 <0.001 80 70–90 <0.001 0.82 0.74–0.91 <0.001
Yes 107 43 46 58 62 66 54–87 62 43–78 69 50–82 0.65 0.51–0.84






< £12,000 52 50 26 0.003 53 28 0.26 62 46–80 <0.001 54 35–72 <0.001 60 50–81 <0.001 0.65 0.51–0.84 <0.001
£12,000–22,999 47 23 11 45 21 79 63–96 72 61–90 80 70–90 0.84 0.68–1.00
£23,000–34,999 46 20 9 39 18 82 61–91 73 63–88 80 70–90 0.77 0.70–1.00
≥ £35,000 56 23 13 36 20 78 70–90 71 61–90 79 68–90 0.80 0.70–0.88
Not known 87 30 42 71 61–87 67 55–82 72 50–82 0.77 0.65–0.84
Tobacco
user
Current 37 57 21 0.001 57 21 0.04 71 40–87 0.08 62 43–87 0.16 71 45–86 0.02 0.69 0.42–0.86 0.04
Former 163 29 47 47 76 75 61–88 68 53–82 75 55–85 0.77 0.63–0.88
Never 80 24 19 34 27 78 66–91 72 59–87 80 70–90 0.80 0.70–0.90
Not known 8 2 66 na 68 na 66 na 0.72 na
Alcohol
user
Current 194 26 51 0.02 40 78 0.007 78 66–91 0.001 71 59–90 0.001 79 62–89 0.004 0.80 0.68–0.88 0.001
Former 73 44 32 60 44 63 52–87 63 46–77 70 50–81 0.70 0.53–0.83
Never 13 23 3 31 4 78 70–91 66 43–78 74 51–85 0.77 0.67–1.00
Not known 8 3 67 na 71 na 73 na 0.74 na
p-value: Fishers exact test (Overall QOL and DT); otherwise Mann–Whitney test (2 comparison groups) or Kruskal–Wallis test (3 or more comparison groups), excluding any categories not known. TTO: Time
trade-off crosswalk values. VAS: Visual analogue scale.
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Logistic regression methods were used (Table 3) to assess the significance of area-level
IMD and patient-level deprivation indicators on HRQOL outcomes after adjustment for
hospital location, gender, age, tumour site, stage, treatment and ACE27 comorbidity. Patient
level indicators relating in one way or another to income and employment were significant
predictors of these HRQOL outcomes after such adjustment. In separate analyses, the
IMD area quintiles were collapsed into a binary variable, into the first two quintiles (i.e.,
those living in the 40% of more deprived English small area neighbourhoods) and those
living in other less deprived areas. This binary IMD variable was significantly predictive
in regard to the worst third of UWQOL social–emotional scores (p = 0.005), the worst
third of EQ-5D-VAS (p = 0.004) and EQ-5D-TTO (p = 0.001) values, after similar casemix
adjustment. For the other HRQOL outcomes of Table 3, it was of borderline significance
(0.05 < p < 0.10).
Table 3. Association of deprivation indicators with HRQOL outcome after adjustment.




Indicators ** Selected in Addition
to Adjustment Variables




Less than good overall
QOL 254 0.24 Financial benefits (0.009) 0.27
Distress thermometer ≥4 254 0.15 Financial benefits 0.001) 0.21
Worst third of UWQOL
Social–emotional
subscale scores
254 0.23 Financial benefits (<0.001), Alcoholuse (0.002) 0.37
Worst third of UWQOL
Physical subscale scores 254 0.32 Currently working (<0.001) 0.38
Worst third of EQ-5D-5L
VAS values 254 0.19 Financial benefits (<0.001) 0.30
Worst third of EQ-5D-5L
TTO crosswalk values 254 0.21
Financial benefits (<0.001), Currently
working (0.009) 0.39
* Adjustment for Age group, gender, trial location, tumour site, tumour staging, treatment and ACE-27 comorbidity as described in Table 1.
** Factors considered were IMD 2019 quintile, currently living in house or flat, currently working, ever been unemployed, financial benefits,
total household income, tobacco use and alcohol use. The NagelKerke R2 statistic (range 0–1) estimates the proportion of the variation
in a binary outcome that can be explained by the predictor variables in the logistic regression model. Missing data were coded only for
household income; otherwise, complete data were available for 254 patients. SES: Socio-Economic Status.
Table 4 shows the significant univariate associations of casemix and SES-related
deprivation-relevant factors with dysfunction on specific UWQOL domains. After similar
casemix adjustment, patient-level indicators relating in one way or another to income
and employment were also significant predictors (p < 0.01) of dysfunction in pain, mood,
swallowing and chewing. The binary-area IMD measure after similar adjustment was also
predictive of dysfunction in mood (p = 0.007) and chewing (p = 0.002).
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Table 4. Significant (p < 0.01) associations of casemix and deprivation-relevant variables with UWQOL domain dysfunction.
Variables Associated
p Value * Observed Nature of Dysfunction
Casemix Dysfunction
Age
Mood 0.004 <55: 21% (15/71) 55–64: 20% (23/116) 65–74: 10% (7/67) ≥75: 0% (0/34)
Anxiety 0.008 <55: 25% (18/71) 55–64: 20% (23/116) 65–74: 10% (7/67) ≥75: 3% (1/34)
Fear of recurrence 0.002 <55: 21% (15/71) 55–64: 12% (14/116) 65–74: 4% (3/67) ≥75: 0% (0/34)
Gender Fear of recurrence 0.001 Male: 7% (13/198) Female: 21% (19/90)
Tumour site
Mood 0.003 Oral: 24% (32/134) Oropharynx: 7% (6/91) Larynx: 10% (4/41) Other: 14% (3/22)
Taste 0.005 Oral: 16% (22/134) Oropharynx: 25% (23/91) Larynx: 7% (3/41) Other: 41% (9/22)
Saliva 0.001 Oral: 28% (38/134) Oropharynx: 48% (44/91) Larynx: 17% (7/41) Other: 45% (10/22)
Overall stage Taste 0.005 Early 0–2: 12% (15/124) Advanced 3–4: 26% (42/164)Saliva <0.001 Early 0–2: 21% (26/124) Advanced 3–4: 45% (73/164)
Treatment *
Shoulder 0.003 S no FF: 15% (14/95) S & FF: 33% (7/21) RT/CT: 2% (1/58) S & RT/CT no FF: 13% (9/68) S & RT/CT & FF: 11% (5/46)
Appearance <0.001 S no FF: 3% (3/95) S & FF: 33% (7/21) RT/CT: 5% (3/58) S & RT/CT no FF: 10% (7/68) S & RT/CT & FF: 17% (8/46)
Swallowing <0.001 S no FF: 3% (3/95) S & FF: 33% (7/21) RT/CT: 24% (14/58) S & RT/CT no FF: 7% (5/68) S & RT/CT & FF: 28% (13/46)
Chewing <0.001 S no FF: 1% (1/95) S & FF: 33% (7/21) RT/CT: 16% (9/58) S & RT/CT no FF: 6% (4/68) S & RT/CT & FF: 37% (17/46)
Taste <0.001 S no FF: 6% (6/95) S & FF: 19% (4/21) RT/CT: 29% (17/58) S & RT/CT no FF: 28% (19/68) S & RT/CT & FF: 24% (11/46)
Saliva <0.001 S no FF: 15% (14/95) S & FF: 24% (5/21) RT/CT: 53% (31/58) S & RT/CT no FF: 47% (32/68) S & RT/CT & FF: 37% (17/46)
ACE27
Appearance 0.007 ACE ‘None’: 6% (8/137), ACE ‘mild’: 8% (8/95) ACE ‘mod/severe’: 21% (12/56)
Chewing 0.004 ACE ‘None’: 8% (11/137), ACE ‘mild’: 13% (12/95) ACE ‘mod/severe’: 27% (15/56)
Speech 0.003 ACE ‘None’: 3% (4/137), ACE ‘mild’: 11% (10/95) ACE ‘mod/severe’: 16% (9/56)
IMD 2019Quintile (Q) Mood 0.008 Q1 (worst): 25% (28/110), Q2: 15% (6/40) Q3: 10% (5/49) Q4: 7% (4/55) Q5 (best): 6% (2/34)Chewing 0.004 Q1 (worst): 21% (23/110), Q2: 20% (8/40) Q3: 4% (2/49) Q4: 5% (3/55) Q5 (best): 6% (2/34)
Currently working
Pain 0.003 Working: 17% (15/88), Not working: 34% (66/192)
Recreation <0.001 Working: 0% (0/88), Not working: 12% (23/192)
Mood 0.001 Working: 5% (4/88), Not working: 20% (39/192)
Swallowing 0.001 Working: 5% (4/88), Not working: 20% (38/192)
Chewing <0.001 Working: 2% (2/88), Not working: 19% (36/192)
Financial benefits
Pain 0.008 Benefits: 37% (40/107), No: 22% (35/158)
Recreation 0.008 Benefits: 13% (14/107) No Benefits: 4% (6/158)
Mood <0.001 Benefits: 25% (27/107) No Benefits: 8% (12/158)
Swallowing <0.001 Benefits: 28% (30/107) No Benefits: 6% (10/158)
Chewing <0.001 Benefits: 25% (27/107) No Benefits: 4% (7/158)
Speech 0.008 Benefits: 13% (14/107) No Benefits: 4% (6/158)
Total Household
income
Mood <0.001 <GBP 12,000: 35% (18/52) GBP 12,000–22,999: 9% (4/47) GBP 23,000–34,999: 11% (5/46) ≥GBP 35,000: 5% (3/56)
Swallowing <0.001 <GBP 12,000: 35% (18/52) GBP 12,000–22,999: 9% (4/47) GBP 23,000–34,999: 9% (4/46) ≥GBP 35,000: 7% (4/56)
Chewing <0.001 <GBP 12,000: 35% (18/52) GBP 12,000–22,999: 11% (5/47) GBP 23,000–34,999: 9% (4/46) ≥GBP 35,000: 2% (1/56)
Tobacco user
Mood <0.001 Current: 41% (15/37) Former: 14% (23/163) Never: 8% (6/80)
Fear of recurrence 0.009 Current: 24% (9/37) Former: 12% (19/163) Never: 5% (4/80)
Alcohol user
Pain 0.004 Current: 25% (48/194) Former: 42% (31/73) Never: 8% (1/13)
Mood 0.004 Current: 12% (23/194) Former: 29% (21/73) Never: 8% (1/13)
Swallowing 0.003 Current: 10% (20/194) Former: 25% (18/73) Never: 31% (4/13)
* Fishers exact test, with analyses using the variables of Table 1 but excluding not known categories. S = Surgery, RT = Radiotherapy, CT = Chemotherapy, FF = Free flap.
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The number of PCI items selected by the 140 PCI patients varied significantly by
overall clinical tumour clinical stage (p < 0.001) and by treatment (p < 0.001) but not by
area IMD or patient-level deprivation indicators. For early-stage tumours, the median
(IQR) number of items was 3 (2–6) while for advanced tumours, it was 7 (3–11). For
patients having surgery without RT/CT or free-flap the number was 3 (1–5); otherwise,
it was 7 (4–10). The most commonly selected PCI items were dry mouth (49%), dental
health/teeth (34%), fear of recurrence (34%), chewing/eating (33%), salivation (33%),
fatigue/tiredness (29%), swallowing (28%) and taste (27%). The ‘financial benefits’ item
was selected by only 4% (6/140). Common patient selections were similar amongst selected
subgroups relevant to area and patient-level deprivation (Table 5).
Table 5. Most commonly selected PCI items (≥20%) for some deprivation-related subgroups.
All Patients
Patient Living in Less
Deprived 60% of IMD
English Small Area
Neighbourhoods
Patient Living in More










n = 288 (All in trial) 138 150 107 110
n = 140 (PCI group) 67 73 49 53
Dry mouth 49
Dental health/teeth 34









Pain in head/neck 21
Cancer treatment 20
Dry mouth 55






































Pain in head/neck 20
Shoulder 20
Dry mouth 47












Socioeconomic factors have a strong influence on HRQOL following HNC, especially
in patients with low SES who show the strongest impairment [27]. The detail on area-level
and individual-level indicators of deprivation collected as part of this randomised trial has
provided an unparalleled opportunity to assess the relationship between SES characteris-
tics and both HRQOL and patient concerns. Although the IMD 2019 is a well recognised
and up-to-date measure combining seven domains of deprivation (income, employment,
education/skills/training, health/disability, crime, barriers to housing/services and living
environment) within relatively focused postcode areas within England, the details asked
of individual trial patients have considerably augmented the assessment of social deter-
minants. In addition, the combination of HRQOL measures (DT, UW-QOL, EQ-5D and
PCI) provides both a general and a head-and-neck-specific patient perspective. In terms
of focusing on financial toxicity incurred during and after treatment, the trial predates a
specific measure such as the Financial Index of Toxicity questionnaire [28], and this could
be included in future studies. Another limitation of this study is that the data come from
two areas in England (Liverpool and Leeds) and might not reflect other regions in the
United Kingdom and internationally. However, although there will be differences between
healthcare systems, any trends in the relationship between social determinants and HRQOL
ought to apply.
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Cancer-related financial hardship, or “financial toxicity” [29–31], is important as this
has implications not only in terms of financial worries during treatment but also potentially
in the longer term. Financial distress is a common concern with respect to quality of life,
coping strategies and supportive care needs in head and neck cancer survivors [32,33].
There are out-of-pocket costs associated with treatment, and these have significant im-
plications on quality of life and survival [34]. These costs are highest during treatment
and gradually decrease over time. Finance is linked to the social determinants of health
and the importance of this to HRQOL outcomes can be underestimated when considering
other aspects such as cancer stage, site and treatment. Patients experiencing cancer-related
financial hardship report worse quality of life, decreased psychosocial well-being and
demonstrate lower treatment adherence [35].
As previously recognised in the literature, differences in HRQOL were seen by cancer
stage and type of treatment; however, there were surprising associations with whether
patients were currently not working, had ever been unemployed, financial benefits received
and overall household income. The importance of these aspects in terms of HRQOL
outcomes following HNC cannot be underestimated, with worse HRQOL scores being
seen across all PRO measures, i.e., DT, UW-WOL subscales and EQ-5D. The relationship
is not as clear regarding the area-level deprivation measure [19], hence the importance of
considering individual indicators of SES.
Financial stability is linked to employment. In our sample, only one-third were aged
65 years or older, yet two-thirds overall were not currently working, and these reported a
significantly worse overall QOL. The ability of patients to return to work is important [32].
Returning to work not only provides income but also adds to self-esteem and reduces
social isolation. Baxi [36] found that in the long-term most survivors of HPV-related
oropharyngeal cancer who were employed at baseline were able to return to work after
taking a break from employment. However, side effects of treatment such as fatigue, pain,
disfigurement, physical morbidity and depression can act as barriers to return to work.
Following HNC, perhaps larynx/hypopharynx patients find a greater degree of workplace
discrimination and inability to return to work [29]. Potentially there is value in improving
HRQOL by a phased return to work and for a better understanding and support in the
workplace of the challenges faced by HNC patients who wish to return to employment [37].
In addition, as a social determinant, just over half of those patients reported never
having been unemployed, and this group had significantly better HRQOL scores. Cur-
rently in 2021, the UK unemployment rate is estimated at 4.8% [38].
HRQOL outcomes in this current study were worse for those with the lowest house-
hold incomes. Individuals with HNC are particularly vulnerable to financial strains given
the established association with lower socioeconomic status [39]. For most patients, the
cancer adds a substantial additional burden to an already financially strained population
and happens disproportionately in the socioeconomically disenfranchised. In the UK, the
government’s department of work and pensions defines low pay with any family earning
less than 60% of the national median pay.
Patient concerns as measured by the PCI showed that the number of issues selected by
patients was significantly associated with tumour stage and treatment but not noticeably
with any of the deprivation indicators. Looking at the items most often selected in relation
to area-level IMD area and patient-level financial benefits, there does not seem to be much
difference. In addition, the PCI ‘financial benefits’ item was not selected that often, though
this might relate more to the context of when the PCI is being used; for example in oncology,
medical follow-up clinics patients might choose not to raise this issue as they might feel that
the focus of the consultation is more about having a cancer disease-free check and about
side effects of treatment and leave financial concerns to other healthcare professionals such
as the Clinical Nurse Specialist. Holistic assessment tools such as the Patient Concerns
Inventory are useful to help identify financially related concerns, particularly at the time
of diagnosis.
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The issue of benefits amongst patients with head and neck cancer has been previ-ously
explored [40]. Over half the patients in that study said that they had suffered fi-nancially
since diagnosis, and half the entire sample said that their financial burden was large or
unbearable. The benefits system is complex, and the current COVID-19 pandemic has
resulted in a large backlog of applications. In our experience from Liverpool and Leeds,
patients often need support with general household bills, especially younger patients who
must take time off work. Small grants are available from Macmillan (UK based cancer
support charity), but patient experiences and needs do vary.
In conclusion, there is an inextricable interrelated relationship between socioeconomic
factors and HNC, both in terms of relative risk for the disease itself and HRQOL outcomes.
The aspect of financial ‘toxicity’ is important as relative poverty is associated with unem-
ployment and depression. Not only should the history of a patient’s employment, work
status, income and reliance on financial benefits be included as case-mix information when
a comprehensive assessment of HRQOL outcomes is being considered, but these aspects
should also be considered as factors to help identify patients during and after treatment,
as they will be at greater risk of having poor outcomes. Addressing the disparity caused
by social determinants is a huge challenge, and innovative solutions are required to tackle
this inequality.
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